论文部分内容阅读
作者用微量细胞毒试验检查了193名肺癌病人在抗癌治疗前和在肿瘤切除、放疗、化疗、免疫疗法后淋巴细胞对同种异体支气管鳞状细胞癌靶细胞的细胞毒性作用。未经抗癌治疗的病人淋巴细胞的细胞毒性:75名治疗前的Ⅰ、Ⅱ、Ⅲ、Ⅳ期病人的平均细胞毒性分别为49.9％,45.2％,40.0％,22.5％。Ⅰ、Ⅱ、Ⅲ期之间在统计学上无明显差别,但Ⅳ期与Ⅰ、Ⅱ、Ⅲ期之间的差别明显。与无恶性瘤的对照组(细胞毒性为32.1％)相比,Ⅰ、Ⅱ、Ⅲ期病人的细胞毒性较大,而Ⅳ期病人的则较小。
The authors examined the cytotoxicity of lymphocytes against allogeneic bronchial squamous cell carcinoma target cells before and after anticancer therapy in 193 lung cancer patients using a microcytotoxicity test. Lymphocyte cytotoxicity in patients without anticancer treatment: The average cytotoxicity of 75 patients before treatment in stage I, II, III, and IV were 49.9%, 45.2%, 40.0%, and 22.5%, respectively. There was no statistically significant difference between stages I, II, and III, but there was a significant difference between stage IV and stages I, II, and III. Compared with the control group without malignant tumors (cytotoxicity was 32.1%), the cytotoxicity of patients with stage I, II, and III was greater, while that of stage IV patients was smaller.